You are here

Article Text

Article menu
Download PDFPDF
Letter
Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
  1. Keisuke Maeshima,
  2. Hirotaka Shibata
  1. Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu, Japan
  1. Correspondence to Dr Keisuke Maeshima, Rheumatology, Faculty of Medicine Graduate School of Medicine, Oita University, Yufu 879-5593, Japan; maeshima{at}oita-u.ac.jp

http://dx.doi.org/10.1136/annrheumdis-2019-216571

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is crucial for the autocrine loop of type I interferons (IFNs) and is located upstream of important systemic lupus erythematosus (SLE)-associated pathogenic proinflammatory cytokines and chemokines. Baricitinib is a JAK 1/2 inhibitor approved for treating rheumatoid arthritis and is also being tested in other diseases, including SLE. Baricitinib improved the proportion of patients with SLE who achieved arthritis or rash resolution; however, the subset of patients with skin involvement was not reported in the study.1 Alopecia is one of the most common cutaneous symptoms in SLE. Patients can exhibit different subtypes of alopecia.2 Diffuse non-scarring hair loss, which is the most frequently observed type of alopecia in patients with SLE, is not life-threatening, but substantially affects quality of life for cosmetic reasons and may reflect latent …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Ethics approval We obtained ethics approval for this study from the Ethical Committee of the Faculty of Medicine, Oita University (approval number: 1722).

    • Provenance and peer review Not commissioned; externally peer reviewed.